Shots:

• The EMA’s CHMP has adopted a positive opinion on a license extension for Vimpat (lacosamide) and Lacosamide UCB (lacosamide) as an adjunctive therapy in the treatment for PGTCS in adults- adolescents- and children from 4 years of age with idiopathic generalized epilepsy
• The CHMP’s positive opinion is based on P-lll study assessing lacosamide as an adjunctive treatment for uncontrolled PGTCS. The therapy lowered the risk of developing a second PGTCS during a 24wks. period and demonstrated a higher rate of freedom from PGTCS during the treatment period
• The company expects the EC’s formal approval decision before the end of 2020- that broaden the clinical application of Vimpat and make a new treatment option available to aid the management of PGTCS

 ­ Ref: UCB | Image: BioExcel